Skip to main content
Close

Skin & Melanoma

Protocols

Ajuvant

SMAJIFN

Adjuvant Therapy of High Risk Malignant Melanoma with High Dose Interferon (HDIFN) alpha-2b   

Advanced - immunotherapy

USMAVFIPI

First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab


USMAVIPI

Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab

USMAVNIV

Treatment of Unresectable or Metastatic Melanoma Using Nivolumab

USMAVPEM

Treatment of Unresectable or Metastatic Melanoma Using Pembrolizumab


Advanced - targeted therapy

USMAVDAB

Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using Dabrafenib 

USMAVDT

Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using daBRAFenib and Trametinib


USMAVI

Treatment of Advanced C-Kit Positive Melanoma Using iMAtinib 


USMAVTRA

Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using Trametinib


USMAVVC

Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using vemURAFenib and cobimetinib

USMAVVEM

Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using Vemurafenib

Advanced - other

SMAVTMZ

Palliative Therapy for Malignant Melanoma with Brain Metastases Using Temozolomide

SMCCNU

Second Line Treatment for Metastatic Malignant Melanoma Using Lomustine (CCNU)

SMDTIC

Therapy for Metastatic Malignant Melanoma Using High Dose Single Agent Dacarbazine (DTIC)

SMTAM

Therapy for Malignant Melanoma Using Tamoxifen

Local therapy

SMILBCG

Therapy for Local or Regional Metastatic Malignant Melanoma Using Intralesional BCG

SMIMI

Topical Immunotherapy for In-Transit Melanoma Metastases, Cutaneous Lymphoma, Basal Cell Carcinoma Using Imiquimod

SMPDT
Topical Therapy for Skin Cancer with PDT (Photodynamic Therapy)

Basal cell carcinoma

USMAVVIS

Treatment of Metastatic or Locally Advanced Basal Cell Carcinoma Using Vismodegib

Merkel cell carcinoma

SMMCCPE

Treatment of recurrent or metastatic Merkel cell carcinoma (MCC) with CISplatin and Etoposide



Terms of use

The information contained in these documents is a statement of consensus of BC Cancer Agency professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. 

Use of these documents is at your own risk and is subject to the BC Cancer Agency's Terms of Use.

Tab Heading
Tab Heading
SOURCE: Skin & Melanoma ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer Agency. All Rights Reserved.

    Copyright © 2017 Provincial Health Services Authority